On March 1, 2022 Aadi Bioscience, Inc. ("Aadi") (Nasdaq:AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will participate in a panel discussion on Tumor-Agnostic Development and one-on-one investor meetings at Cowen’s 42nd Annual Health Care Conference, to be held virtually March 7-9, 2022 (Press release, Aadi Bioscience, MAR 1, 2022, https://aadibio.com/aadi-bioscience-to-participate-in-panel-discussion-on-tumor-agnostic-development-at-cowens-42nd-annual-health-care-conference/ [SID1234609357]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Panel Details
Topic: Tumor-Agnostic Development
Date: Tuesday, March 8th, 2022
Time: 12:50 PM EST
Webcast Link: Click Here
A replay of the panel discussion will also be available for 30 days on Aadi’s website within the News/Events & Presentations section.